secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001140361-24-001194
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M
--------------------------------------------------------------------------------

- Q4 2023 preliminary revenue $72-74M; full year $256-258M.
- FY2024 revenue guidance raised to >$320M from $290M; FY2025 to >$370M from $335M.
- FY2024 net income expected >$60M (from $55M) and adjusted EBITDA ~$85M.
- New growth: manufacturing yield enhancement and S. pneumonia hyperimmune globulin (potential peak revenue $300-500M).
- ASCENIV label expansion via pediatric study progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/0001140361-24-001194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/ef20018240_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-001194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer